The Annals of Applied Statistics 2015, Vol. 9, No. 4, 2215–2236 DOI: 10.1214/15-AOAS860 © Institute of Mathematical Statistics, 2015

ON THE ANALYSIS OF TUBERCULOSIS STUDIES WITH INTERMITTENT MISSING SPUTUM DATA¹

By Daniel Scharfstein^{*}, Andrea Rotnitzky[†], Maria Abraham[‡], Aidan McDermott^{*}, Richard Chaisson^{*} and Lawrence Geiter[§]

Johns Hopkins University^{*}, Universidad Torcuato Di Tella[†], Statistics Collaborative[‡] and Otsuka Novel Products[§]

In randomized studies evaluating treatments for tuberculosis (TB), individuals are scheduled to be routinely evaluated for the presence of TB using sputum cultures. One important endpoint in such studies is the time of culture conversion, the first visit at which a patient's sputum culture is negative and remains negative. This article addresses how to draw inference about treatment effects when sputum cultures are intermittently missing on some patients. We discuss inference under a novel benchmark assumption and under a class of assumptions indexed by a treatment-specific sensitivity parameter that quantify departures from the benchmark assumption. We motivate and illustrate our approach using data from a randomized trial comparing the effectiveness of two treatments for adult TB patients in Brazil.

1. Introduction. In the design of randomized studies evaluating competing treatments for patients with tuberculosis (TB), it is common to culture sputum for the presence of TB at regularly scheduled clinic visits over a specified time horizon. A primary goal in such studies is to estimate the treatment-specific distribution of the time of culture conversion [European Medicines Agency, Committee for Medicinal Products for Human Use (2010)]. Culture conversion is said to have occurred for a patient at a given visit if the sputum cultures for that visit and all subsequent visits are negative. A key complication in the analysis arises when culture results are missing at some visits, because the culture was contaminated, the patient could not produce sputum, or the patient did not show up. Culture conversion status at a given visit is unknown when from that visit onward at least

Received May 2013; revised July 2015.

¹Supported in part by NIH Grants CA85295, CA183854, AI051164, P30 MH066247 and Otsuka Pharmaceutical Development and Commercialization, Inc. and contracts from the Food and Drug Administration and the Patient-Centered Outcomes Research Institute.

Key words and phrases. Culture conversion, curse of dimensionality, exponential tilting, reverse-time hazard, sensitivity analysis.

This is an electronic reprint of the original article published by the Institute of Mathematical Statistics in *The Annals of Applied Statistics*, 2015, Vol. 9, No. 4, 2215–2236. This reprint differs from the original in pagination and typographic detail.

one culture result is missing *and* all recorded culture results are negative. For a given patient, the set of visits with unknown culture conversion status is empty, or it consists of either a single visit or a set of consecutive visits. If the set is not empty, the time of culture conversion will be known to lie in an interval. The time may not be interval-censored in the classical sense, however, because certain data configurations may imply that culture conversion cannot occur at certain visit times within the interval. To distinguish this data structure from classic interval censoring, we refer to the set of feasible times that are compatible with an individual's data as the coarsening set. The coarsening set can include a single point or a set of points.

The treatment-specific distribution of time of culture conversion is not identified without untestable assumptions about the distribution of culture conversion status within the coarsening sets. There are countless ways of imposing such assumptions. The "worst-case" and "best-case" assumptions, leading to bounds on the treatment-specific distribution of time of culture conversion, are that the missing culture associated with the latest visit time at which culture conversion status is unknown is positive and that the missing cultures associated with all visit times at which culture conversion status is unknown are negative, respectively. In considering alternative assumptions, it is natural to condition on as much of the relevant data as possible. In addition to conditioning on observed culture results, it is natural to condition on auxiliary factors that are associated with the unknown results inside the coarsening set.

Most TB studies collect a key auxiliary time-varying variable. Sputum specimens are also evaluated by smear, and the results of the smear may be available when a culture is contaminated. Sputum smear is a less reliable assessment of clinical tuberculosis than sputum culture. It relies on the visualization of the bacteria through a microscope after staining of sputum with dyes that allows the microscopist to see so-called acid-fast TB bacteria. Sensitivity of the sputum smear is about 0.5, but it can vary by staining method used and clinical population. In contrast, sputum culture involves breaking down the sputum (which is very viscous), decontaminating the specimen to kill bacteria other than the mycobacteria, and inoculating it on culture media where the bacilli can grow. Sensitivity of the sputum culture is about 0.8–0.85 [American Thoracic Society (2000)]. Roughly 65% of those with a positive culture are expected to have a positive smear, and nearly 100% of those with a positive smear are expected to have a positive culture [American Thoracic Society (2000)].

Another important auxiliary variable is baseline cavitation status. Patients with pulmonary tuberculosis who have cavities seen on a chest radiograph (cavitary tuberculosis) are more likely to have positive sputum smears, as they harbor larger numbers of tubercle bacilli than patients without cavities. It generally takes longer for patients with cavitary tuberculosis to convert their smears and cultures to negative during treatment, as they have a larger bacterial load and the therapy must kill more organisms.

This article is motivated by data from a randomized TB study previously analyzed by Conde et al. (2009).² This phase II, double-blind, randomized trial compared moxifloxacin vs. ethambutol in adults with smear-positive tuberculosis at baseline in a hospital in Rio de Janeiro, Brazil. All 170 patients randomized (85 to each treatment arm) into the study were treated with a background regimen of isoniazid, rifampicin and pyrazinamide. Patients with a negative or contaminated smear or with drug-resistant Mycobacterium tu*berculosis* at baseline were excluded from the analysis, resulting in an analysis sample of 74 and 72 patients in the moxifloxacin and ethambutol groups, respectively. Treatment was scheduled to be given five days per week and was to be directly observed by study personnel. Sputum specimens (spontaneous or induced) were scheduled to be collected at baseline and every week for 8 weeks. The specimens were to be evaluated by both smear and culture testing. In this study, 55.4% and 62.5% of patients in the moxifloxacin and ethambutol arms, respectively, had complete culture data through week 8. Time of culture conversion could be determined for 64.9% and 72.2%of patients in these arms; the remaining patients had their time of culture conversion coarsened.

In this article, we develop a method that estimates the treatment-specific distribution of time of culture conversion under a class of assumptions on the distribution of the coarsened time of culture conversion that conditions on *all of the relevant available data*, including sputum cultures, sputum smears and baseline data. Each assumption in the class is indexed by a treatment-specific sensitivity-analysis parameter which quantifies the magnitude of discrepancy from a specific benchmark assumption. In Section 2 we provide a preview of our proposed method. In Section 3 we discuss our modeling assumptions and approach to inference. Section 4 presents an analysis of data from the Conde et al. (2009) study. The article concludes with a discussion.

2. Preview. Our approach starts by imposing nontestable assumptions that identify the conditional distribution of time to culture conversion given the data, for every data configuration for which time of culture conversion is unknown. The crucial methodological challenge then is to make sensible identifying assumptions. Because time of culture conversion is determined by the results of sputum cultures, these assumptions ultimately identify the visit-specific probabilities of the last positive sputum culture given the data.

 $^{^{2}}$ The data set provided to us differs slightly from that of Conde et al. (2009). There are small differences in the number of observed cultures and the number of observed negative cultures at each week. All analyses reported in this article are based on the data provided to us.

Lack of culture conversion at a given visit can be determined without full knowledge of all subsequent results if the culture at that visit is positive or at least one subsequent culture is observed to be positive. It turns out that with "proper bookkeeping," we can achieve identifiability by imposing assumptions that suffice to identify the distribution of time of culture conversion but do not fully identify the joint distribution of results across visits. These conditions identify the reverse-time conditional hazards of time of culture conversion. This section illustrates these issues by means of an example.

The sputum culture data collected on one patient in the study illustrate the coarsening structure of culture conversion status and the time of culture conversion. The sputum culture data for this patient, whom we call Mary, are displayed in the first line of Table 1; the associated culture conversion statuses are displayed in line 2. Missing values are indicated by either Ror I, depending on whether they are relevant or irrelevant for establishing culture conversion status. Mary has negative cultures at visits 4, 6, 7 and 8 and a positive culture at visit 2. She is a culture converter at visits 6, 7 and 8 (labeled "Y" in the second line), known not to be a culture converter at visits 1 and 2 (labeled "N" in the second line) and has unknown culture conversion status at visit 3, 4 and 5 (labeled U in the second line). First, even though her culture status at visit 1 (labeled I in the first line) is missing, it is irrelevant for determining whether she is a culture converter at that visit, because she has a positive culture at visit 2 and therefore cannot be a culture converter at visit 1. Second, missingness of cultures at visits 3 and

Line		Visit							Coarsening	
		1	2	3	4	5	6	7	8	set
$\frac{1}{2}$	Culture results Conversion?	I N	+ N	$R \\ U$	\overline{U}	$R \\ U$	– Y	– Y	– Y	$\{3, 4, 6\}$
$\frac{3}{4}$	Culture results Conversion?	I N	$^+_{ m N}$	I N	– N	$^+_{ m N}$	$_{\rm Y}^{-}$	$_{\rm Y}^{-}$	$_{ m Y}^{-}$	$\{6\}$
$5 \\ 6$	Culture results Conversion?	I N	$^+$ N	R U	– Y	– Y	– Y	-Y	-Y	$\{3, 4\}$
7 8	Culture results Conversion?	I N	$^+$ N	$^+_{ m N}$	-Y	-Y	-Y	-Y	-Y	<i>{</i> 4 <i>}</i>
9 10	Culture results Conversion?	I N	$^+$ N	_ Y	$_{\rm Y}^{-}$	$_{\rm Y}^{-}$	– Y	_ Y	$_{\rm Y}^{-}$	{3}

 TABLE 1

 Examples of patient data. - denotes negative culture, + denotes positive culture, U

denotes unknown, I denotes a missing culture result that is irrelevant for determining culture conversion, and R denotes a missing culture result that is relevant for determining culture conversion 5 (labeled R in the first line) affects our ability to determine her culture conversion status at visits 3, 4 and 5 because all cultures after visit 5 are negative and the culture at visit 4 is also negative. So even though Mary has a negative culture at visit 4, her culture conversion status is not known at that visit. Third, the visits at which culture conversion status is unknown are consecutive: the earliest and latest visits are 3 and 5, respectively. Finally, the coarsening set for time of culture conversion comprises visits 3, 4 and 6. This follows because if the culture at visit 5 were positive, then the time of culture conversion would be visit 6, and if the culture at visit 5 were negative, the time of culture conversion would be either visit 3 or visit 4, depending on the result at visit 3.

To illustrate our approach for identifying the conditional distribution of time of culture conversion given the data, consider subset A, the subset of patients with the same observed data as Mary. Specifically, we must model the probability that the cultures at visits 3 and 5 are both negative (in which case the time of culture conversion is visit 3), the probability that the culture at visit 3 is positive and the culture at visit 5 is negative (in which case the time of culture conversion is visit 4), and the probability that the culture at visit 5 is positive (in which case the time of culture conversion is visit 6). In modeling these probabilities, it is natural to consider two chronological factorizations. In forward time, we would need to model the probability of a negative culture at visit 3, the conditional probability of a negative culture at visit 5 given a negative culture at visit 3, and the conditional probability of a negative culture at visit 5 given a positive culture at visit 3. In reverse time, we would need to model (i) the probability of a positive culture at visit 5 and (ii) the conditional probability of a positive culture at visit 3 given a negative culture at visit 5. We use this latter factorization as it requires fewer modeling assumptions.

We first turn to the task of imposing assumptions that identify (i). Our identifying assumption specifies that (i) is the same as the probability of a positive culture at visit 5 among patients with the same data as in subset A, with the exception that they have an observed culture at visit 5. The observed culture results for these patients are depicted in lines 3 and 5. These patients have observed culture conversion status as depicted in lines 4 and 6. The probability (i) is then assumed to be equal to the ratio of the proportion of patients with observed results as in line 3 to the sum of the proportions of patients with observed results as in lines 3 and 5.

Next, we turn to the task of imposing assumptions that identify (ii). Our identifying assumption specifies that (ii) is the same as the probability of a positive result at visit 3 among patients with the same pattern of observed cultures as that in line 5, with the exception that they have an observed culture at visit 3. The results of these patients are depicted in lines 7 and 9 with associated culture conversion status in lines 8 and 10. The probability

(ii) is then assumed to be equal to the ratio of the proportion of patients with observed cultures as in line 7 to the sum of the proportions of patients with observed cultures as in lines 7 and 9.

In data sets of typical size, we will not be able to obtain reliable estimates of the proportion of patients who have specific patterns of observed data because of the curse of dimensionality. As a result, our inference will require dimension-reduction assumptions. We will use fully parametric models for the treatment-specific distributions of the data. These models are described in Section 3.4.

In Section 3.3 we evaluate the sensitivity of our results to our identifying assumptions by conducting inference under a class of exponential tilt deviations from the assumed conditional probabilities for the unobserved culture conversion status.

3. Formalization of the problem. Since we focus on inference about the time of culture conversion, separately for each treatment arm, we consider, until Section 3.5, only data from one arm and suppress notational dependence on treatment assignment.

3.1. Data structure and notation. Let X denote baseline cavitation status (1 for cavitation, 0 otherwise), C_k denote the indicator that the culture is negative at visit k (1 for negative, 0 for positive) and S_k denote the indicator that the smear is negative at visit k (1 for negative, 0 for positive). Let M_k^c and M_k^s be the indicators that C_k and S_k are missing, respectively (1 for missing, 0 for observed). The data recorded on an individual at visit k are a realization of the random vector $O_k = (M_k^c, C_k^{\text{obs}}, M_k^s, S_k^{\text{obs}})$, where $C_k^{\text{obs}} = C_k$ if C_k is observed and C_k^{obs} is empty otherwise and S_k^{obs} is defined likewise.

Let K denote the number of scheduled post-baseline visits. For any collection of random vectors $\{W_k\}_{1 \le k \le K}$, we use the notation $\overline{W}_k = (W_1, \ldots, W_k)$. With this notation, the data recorded on an individual throughout the entire study are a realization of the random vector $\mathbf{O} = (X, \overline{O}_K)$. It is useful to denote the auxiliary data by $V \equiv (X, \overline{M}_K^s, \overline{S}_K^{obs})$. For a random variable or vector which is a function of \mathbf{O} (e.g., V, L and R), we use lowercase notation (e.g., v, l and r) to denote the realization associated with a given realization \mathbf{O} of \mathbf{O} .

Define time of culture conversion T to be the earliest visit such that sputum cultures are negative from that visit onward if such a visit exists and T = K + 1 otherwise. With observed data **O** on a patient, T belongs either to a set with a single visit time (in which case T is determined from **O**) or to a set with multiple visit times, not necessarily consecutive. We denote the coarsening set where T is known to lie by \mathcal{T} . Given **O**, T is determined (i.e., the set \mathcal{T} has one element) unless either: (i) the culture at visit K is missing, that is, $M_K^c = 1$, or

(ii) there exists a visit k < K with a missing culture, that is, $M_k^c = 1$, such that all subsequent visits have sputum cultures that are either negative or missing, that is, $M_i^c = 1$ or $C_i^{\text{obs}} = 1$ for j > k.

When either (i) or (ii) occurs, \mathcal{T} will have multiple visit times. We denote the lowest visit number in the set by L, which is the earliest visit k where the sputum cultures are either missing or negative at and subsequent to visit k. We denote the largest visit number in the set by R + 1, where R = K if the culture at visit K is missing (i.e., $M_K^c = 1$) and R = k (k < K) if at visit k the sputum culture is missing and at all subsequent visits the sputum cultures are recorded and negative. The other times in the coarsening set include all visit numbers k such that L < k < R + 1 and $M_{k-1}^c = 1$.

Formally, our inferential goal is to estimate the distribution of time of culture conversion, that is, P[T = k] for k = 1, ..., K, based on n i.i.d. realizations of the vector **O**. We use the subscript i to denote data for the *i*th individual.

In Section 3.2 we formally describe the identifying assumptions on which our benchmark analysis relies. These assumptions were illustrated in Section 2. The assumptions are "identifying" in the sense that once they are imposed, we are able to express P[T = k] for k = 1, ..., K as a function of the distribution of the observed data **O** and, consequently, we can hope, to estimate P[T = k] consistently. Subsequently, we propose models for departures from the benchmark assumptions that form the basis of our proposed sensitivity analysis. Specifically, our sensitivity analysis consists of repeating estimation of P[T = k] under various plausible departures from the benchmark assumptions.

Both our benchmark analysis and the models for our sensitivity analysis rely on assumptions that identify the conditional distribution of T given the observed data **O**. The marginal distribution of T is then obtained as the mixture of the, now identified, conditional distribution of T given **O** mixed over the distribution of the observed data **O**.

3.2. Benchmark identifying assumptions. To help guide our choice of benchmark identifying assumptions, we first note that since $P[T = k | \mathbf{O}] = 0$ if $k \notin \mathcal{T}$ and $P[T = k | \mathbf{O}] = 1$ if $k \in \mathcal{T}$ and $|\mathcal{T}| = 1$, we only need assumptions that suffice to identify $P[T = k | \mathbf{O}]$ when $k \in \mathcal{T}$ and $|\mathcal{T}| > 1$. Thus, we proceed in reverse order through the set \mathcal{T} by postulating assumptions that identify first $P[T = R + 1 | \mathbf{O}]$ and then sequentially $P[T = k | T \leq k, \mathbf{O}]$, where $k \in \mathcal{T}$, L < k < R + 1. This iterative procedure results in assumptions that identify $P[T = k | \mathbf{O}]$ for all $k \in \mathcal{T}$. This follows because $P[T = R + 1 | \mathbf{O}]$ is identified

and for $k \in \mathcal{T}, k < R+1, P[T = k | \mathbf{O}]$ equals

$$P[T \neq R+1|\mathbf{O}] \left\{ \prod_{\substack{k < s < R+1\\s \in \mathcal{T}}} P[T \neq s|T \leq s, \mathbf{O}] \right\} P[T = k|T \leq k, \mathbf{O}].$$

To guide our choice of benchmark assumptions for identifying $P[T = r + 1 | \mathbf{O} = \mathbf{o}]$, we first note that given $\mathbf{O} = \mathbf{o}$ the event T = r + 1 occurs if and only if the culture at visit r is positive, that is, if $C_r = 0$. Our benchmark assumption equates the unidentified probability $P[T = r + 1 | \mathbf{O} = \mathbf{o}]$ with the identified probability that $C_r = 0$ in the subset of patients for which $\mathbf{O} = \mathbf{o}^{(r)}$, where $\mathbf{o}^{(r)}$ agrees with \mathbf{O} in all its components except that the culture at visit r is observed. Now we write the event $\mathbf{O} = \mathbf{o}$ as the event

(3.1)
$$M_{r}^{c} = 1, \overline{M}_{r-1}^{c} = \overline{m}_{r-1}^{c}, \overline{C}_{r-1}^{obs} = \overline{c}_{r-1}^{obs}, V = v, M_{j}^{c} = 0, C_{j} = 1$$
(3.1) for $r+1 \le j \le K$

we define the event $\mathbf{O} = \mathbf{o}^{(r)}$ as the event

$$M_r^c = 0, \overline{M}_{r-1}^c = \overline{m}_{r-1}^c, \overline{C}_{r-1}^{\text{obs}} = \overline{c}_{r-1}^{\text{obs}}, V = v, M_j^c = 0, C_j = 1$$
for $r+1 \le j \le K$

and we postulate that

(3.2)
$$P[T = r + 1 | \mathbf{O} = \mathbf{o}] = P[T = r + 1 | \mathbf{O} = \mathbf{o}^{(r)}].$$

Next we consider assumptions that identify $P[T = k | T \leq k, \mathbf{O} = \mathbf{o}]$ for $k \in \mathcal{T}, l < k < r + 1$. Once again, given $(T \leq k, \mathbf{O} = \mathbf{o})$, the event T = k occurs if and only if the culture result at visit k - 1 is positive, that is, $C_{k-1} = 0$. Because $k \in \mathcal{T}, l < k < r + 1$, we know that C_{k-1} is missing, that is, $M_{k-1}^c = 1$. Our benchmark assumption in this case equates the probability $P[T = k | T \leq k, \mathbf{O} = \mathbf{o}]$ with the identified probability that T = k (which equates to the event $C_{k-1} = 0$) in the subset of patients for which $\mathbf{O} = \mathbf{o}^{(k-1)}$, where $\mathbf{o}^{(k-1)}$ differs from the subset of patients with $(T \leq k, \mathbf{O} = \mathbf{o})$ only in that a sputum culture is observed at visit k - 1 and the event $T \leq k$ is observed to occur (i.e., $M_j^c = 0$ and $C_j = 1$ for all $k \leq j \leq K$). Formally, with the event $\mathbf{O} = \mathbf{o}^{(k-1)}$ as the event

$$M_{k-1}^{c} = 0, \overline{M}_{k-2}^{c} = \overline{m}_{k-2}^{c}, \overline{C}_{k-2}^{obs} = \overline{c}_{k-2}^{obs}, V = v, M_{j}^{c} = 0, C_{j} = 1$$
for $k \le j \le K$

and assume

(3.3)
$$P[T = k | T \le k, \mathbf{O} = \mathbf{o}] = P[T = k | \mathbf{O} = \mathbf{o}^{(k-1)}].$$

Patients in the subset defined by $(T \le k, \mathbf{O} = \mathbf{o})$ and subjects in the subset $\mathbf{O} = \mathbf{o}^{(k-1)}$ have the same baseline factors and the same recorded history of the auxiliary smear sputums throughout the study, as well as the same recorded history of sputum cultures up to visit k-2.

Finally, for a realization $\mathbf{O} = \mathbf{o}$ where $|\mathcal{T}| > 1$, $P[T = l | T \le l, \mathbf{O} = \mathbf{o}] = 1$.

3.3. Sensitivity analysis. The benchmark assumptions (3.2) and (3.3) are untestable. For realizations $\mathbf{O} = \mathbf{o}$ with $|\mathcal{T}| > 1$, the following exponential tilt model [Barndorff-Nielsen and Cox (1994)] expresses departures from our benchmark assumptions:

(3.4)
$$P[T = r + 1 | \mathbf{O} = \mathbf{o}] = \frac{P[T = r + 1 | \mathbf{O} = \mathbf{o}^{(r)}] \exp(\alpha)}{h_{r+1}(\mathbf{o}^{(r)}; \alpha)}$$

and for $k \in \mathcal{T}$, l < k < r + 1,

(3.5)
$$P[T = k | T \le k, \mathbf{O} = \mathbf{o}] = \frac{P[T = k | \mathbf{O} = \mathbf{o}^{(k-1)}] \exp(\alpha)}{h_k(\mathbf{o}^{(k-1)}; \alpha)}$$

where α is fixed and given and $h_k(\mathbf{o}^{(k-1)}; \alpha)$ are normalizing constants equal to $E[\exp{\{\alpha I(T=k)\}}|\mathbf{O}=\mathbf{o}^{(k-1)}]$ for $k \in \mathcal{T}, l < k \leq r+1$. Under this exponential tilt model,

$$\frac{\operatorname{odds}(P[T=r+1|\mathbf{O}=\mathbf{o}])}{\operatorname{odds}(P[T=r+1|\mathbf{O}=\mathbf{o}^{(r)}])} = \frac{\operatorname{odds}(P[T=k|T\leq k,\mathbf{O}=\mathbf{o}])}{\operatorname{odds}(P[T=k|\mathbf{O}=\mathbf{o}^{(k-1)}])} = \exp(\alpha).$$

Thus, the magnitude of α quantifies the departure from our benchmark assumptions. When $\alpha > 0$ (< 0), $P[T = r + 1 | \mathbf{O} = \mathbf{o}]$ is greater (less) than $P[T = r + 1 | \mathbf{O} = \mathbf{o}^{(r)}]$ and $P[T = k | T \le k, \mathbf{O} = \mathbf{o}]$ is greater (less) than $P[T = r + 1 | \mathbf{O} = \mathbf{o}^{(r)}]$ $k[\mathbf{O} = \mathbf{o}^{(k-1)}]$. As $\alpha \to \infty$ $(-\infty)$, $P[T = r+1|\mathbf{O} = \mathbf{o}]$ and $P[T = k|T \le k, \mathbf{O} = \mathbf{o}]$ **o**] go to one (zero). When $\alpha \to \infty$ ($-\infty$), the "worst-case" and "best-case" bounds described in the Introduction are attained. $\alpha = 0$ corresponds to the benchmark assumption. To facilitate sensitivity analysis, our class of models assumes that the departures from the benchmark assumption are not time-specific.

3.4. Modeling. For specified α , estimation of the distribution of time of culture conversion depends on our ability to estimate for each realization $\mathbf{O} = \mathbf{o}$ with $|\mathcal{T}| > 1$, $P[T = k | \mathbf{O} = \mathbf{o}^{(k-1)}]$ for $k \in \mathcal{T}, l < k \leq r+1$. However, in practice, these probabilities cannot be estimated nonparametrically. Therefore, we use a parametric model for the law of the observed data **O** given baseline cavitation status X. This model induces parametric models for $P[T = k | \mathbf{O} = \mathbf{o}^{(k-1)}], k \in \mathcal{T}, l < k \leq r+1$, that ultimately enable estimation of $P[T = k | \mathbf{O} = \mathbf{O}]$ by borrowing information across strata $\mathbf{O} = \mathbf{o}^{(k-1)}$. We first recall that $\mathbf{O} = (X, \overline{O}_K)$, where $O_k = (M_k^c, C_k^{\text{obs}}, M_k^s, S_k^{\text{obs}})$ are the

data available at visit k. We model the law of **O** by modeling the distribution

of O_k given \overline{O}_{k-1} and X for all k = 1, ..., K, where $\overline{O}_0 = \emptyset$. We use separate logistic regression models for:

1. the probability of $M_k^c = 1$ given \overline{O}_{k-1} and X, that is,

(3.6)
$$\operatorname{logit}\{P[M_k^c = 1 | \overline{O}_{k-1}, X]\} = a(k, \overline{O}_{k-1}, X; \gamma^{(a)}),$$

2. the probability that $C_k^{\text{obs}} = 1$ given $M_k^c = 0$, \overline{O}_{k-1} and X, that is,

(3.7)
$$\log i \{ P[C_k^{obs} = 1 | M_k^c = 0, \overline{O}_{k-1}, X] \} = b(k, \overline{O}_{k-1}, X; \gamma^{(b)}),$$

3. the probability that $M_k^s = 1$ given M_k^c , C_k^{obs} , \overline{O}_{k-1} and X, that is,

(3.8) logit {
$$P[M_k^s = 1 | M_k^c, C_k^{\text{obs}}, \overline{O}_{k-1}, X]$$
} = $c(k, M_k^c, C_k^{\text{obs}}, \overline{O}_{k-1}, X; \gamma^{(c)})$,

4. the probability that $S_k^{obs} = 1$ given $M_k^s = 0$, M_k^c , C_k^{obs} , \overline{O}_{k-1} and X, that is,

(3.9)
$$\log it \{ P[S_k^{obs} = 1 | M_k^s = 0, M_k^c, C_k^{obs}, \overline{O}_{k-1}, X] \} = d(k, M_k^c, C_k^{obs}, \overline{O}_{k-1}, X; \gamma^{(d)}),$$

where $a(\cdot)$, $b(\cdot)$, $c(\cdot)$ and $d(\cdot)$ are specified functions of their arguments and $\gamma^{(a)}$, $\gamma^{(b)}$, $\gamma^{(c)}$ and $\gamma^{(d)}$ are unknown parameter vectors.

For the distributions in (3.7) and (3.9) we need not consider the cases $M_k^c = 1$ and $M_k^s = 1$, respectively, because for such settings the conditional distributions are degenerate (C_k^{obs} is empty when $M_k^c = 1$, and S_k^{obs} is empty when $M_k^s = 1$).

3.5. Inference. Under models (3.6)–(3.9) we can express for all realizations $\mathbf{O} = \mathbf{o}$ with $|\mathcal{T}| > 1$ the conditional probability $P[T = k | \mathbf{O} = \mathbf{o}^{(k-1)}]$ for $k \in \mathcal{T}, l < k \leq r+1$ as given functions of $\mathbf{o}^{(k-1)}$ and $\gamma = (\gamma^{(a)}, \gamma^{(b)}, \gamma^{(c)}, \gamma^{(d)})$ whose expressions, for the special case where the right-hand sides of (3.6)–(3.9) only depend on O_{k-1} , are given in the Appendix. We denote this expression as $P[T = k | \mathbf{O} = \mathbf{o}^{(k-1)}; \gamma]$. Consequently, if we additionally assume models (3.4) and (3.5), then we can express $P[T = r+1 | \mathbf{O} = \mathbf{o}]$ and $P[T = k | T \leq k, \mathbf{O} = \mathbf{o}]$ ($k \in \mathcal{T}, l < k \leq r$) as given functions, $P[T = r+1 | \mathbf{O} = \mathbf{o}; \gamma; \alpha]$ and $P[T = k | T \leq k, \mathbf{O} = \mathbf{o}; \gamma; \alpha]$ of \mathbf{o}, γ and α .

The first step is to estimate γ using maximum likelihood; denote this estimator by $\hat{\gamma}$. This can be done using standard logistic regression software. This step does not rely on specification of the sensitivity analysis parameter α .

For fixed α , we estimate P[T = k] by $\widehat{P}[T = k; \alpha] = \frac{1}{n} \sum_{i=1}^{n} \widehat{P}[T_i = k; \alpha]$, where $\widehat{P}[T_i = k; \alpha]$ has one of four expressions depending on k and \mathbf{O}_i . If $k \notin \mathcal{T}_i$, then $\widehat{P}[T_i = k; \alpha] = 0$; if $|\mathcal{T}_i| = 1$ and $k \in \mathcal{T}_i$, then $\widehat{P}[T_i = k; \alpha] = 1$; if $|\mathcal{T}_i| > 1$ and $k = R_i + 1$, then $\widehat{P}[T_i = k; \alpha] = P[T = R_i + 1 | \mathbf{O} = \mathbf{O}_i; \widehat{\gamma}; \alpha]$; if $|\mathcal{T}_i| > 1$ and $k \in \mathcal{T}_i, k < R_i + 1$, then $\widehat{P}[T_i = k; \alpha]$ equals

$$P[T \neq R_i + 1 | \mathbf{O} = \mathbf{O}_i; \widehat{\gamma}; \alpha] \left\{ \prod_{\substack{k < s < R_i + 1 \\ s \in \mathcal{T}_i}} P[T \neq s | T \le s, \mathbf{O} = \mathbf{O}_i; \widehat{\gamma}; \alpha] \right\}$$
$$\times P[T = k | T \le k, \mathbf{O} = \mathbf{O}_i; \widehat{\gamma}; \alpha].$$

To compare the treatment-specific distributions of time to culture conversion, one can estimate a common treatment effect over time. Toward this end, one can use the logistic model for discrete survival data proposed by Cox (1972). This model assumes that

$$\frac{h_z(k)}{1 - h_z(k)} = \tau_k \exp(\beta z), \qquad k = 1, \dots, K, z = 0, 1,$$

where z denotes treatment group, $h_z(k) = P_z[T = k | T \ge k]$, and $\tau_1, \ldots, \tau_K \ge 0$. Here $\exp(\beta)$ is the ratio of the odds of first becoming a culture converter at visit k given culture conversion at or after visit k, comparing moxifloxacin with ethambutol.

To estimate the model parameters, one can use equally weighted minimumdistance estimation [Newey and McFadden (1994)]. Specifically, for each choice of α_z (z = 0, 1), we minimize the following objective function:

$$\sum_{z=0}^{1} \sum_{k=1}^{K} \left\{ \frac{\widehat{h}_z(k;\alpha_z)}{1 - \widehat{h}_z(k;\alpha_z)} - \tau_k \exp(\beta z) \right\}^2$$

with respect to $\tau_1, \ldots, \tau_K \geq 0$ and β , where $\hat{h}_z(k; \alpha_z) = \hat{P}_z[T = k | T \geq k; \alpha_z]$. For each choice of α_z (z = 0, 1), this method finds the "closest" fitting logistic model to the "data:" { $\hat{h}_z(k; \alpha_z) : k = 1, \ldots, K, z = 0, 1$ }. Even if the model is incorrectly specified, it can still be used to provide a valid test of the null hypothesis of no treatment effect.

To estimate the standard error of our estimator, we propose the use of nonparametric bootstrap.

4. Data analysis. Figure 1 displays the treatment-specific observed culture results, with rows denoting patients, columns denoting visits, black indicating a positive culture, white indicating a negative culture and gray indicating a missing culture. Figure 2 displays the treatment-specific coarsening sets for time of culture conversion, with white and gray indicating the infeasible and feasible points, respectively.

By chance, the treatment groups were not balanced with respect to cavitation status at baseline; 81.1% and 56.9% have cavitation in the moxifloxacin and ethambutol arms, respectively. It is essential that our analysis adjust for




FIG. 1. Treatment-specific observed culture results, with rows denoting patients, columns denoting visits, black indicating a positive culture, white indicating a negative culture and gray indicating a missing culture.

this key confounder. For each treatment group, we estimate the distribution of time of culture conversion by a weighted average of cavitation-specific distribution of time of culture conversion. The weights are taken to be the marginal (i.e., not conditional on treatment arm) proportion of patients with and without cavitation at baseline, respectively.

In our data analysis, we considered parsimonious models for the righthand sides of (3.6)–(3.9). Our choice of models was guided by substantive considerations discussed with our scientist collaborators and by data analytic model-fitting techniques. Our final model assumed that the right-hand sides of (3.6)–(3.9) depended only on $O_{k-1} = (M_{k-1}^c, C_{k-1}^{obs}, M_{k-1}^s, S_{k-1}^{obs})$ (i.e., not on the other components of \overline{O}_{k-1}), and the final model for (3.8) further assumed that $c(k, M_k^c, C_k^{obs}, O_{k-1}, X; \gamma^{(c)})$ did not depend on C_k^{obs} and C_{k-1}^{obs} . The latter assumption was imposed because missingness of a sputum culture at visit k is highly predictive of missingness of smear sputums at visits k and k - 1. In the Appendix we show that when the function $c(k, M_k^c, C_k^{obs}, O_{k-1}, X; \gamma^{(c)})$ does not depend on C_k^{obs} and C_{k-1}^{obs} for all k,




FIG. 2. Treatment-specific coarsening sets, with rows denoting patients, columns denoting visits, white indicating infeasible points and gray indicating feasible points.

 $P[T = k | \mathbf{O} = \mathbf{o}^{(k-1)}]$ does not depend on $c(k, M_k^c, C_k^{\text{obs}}, O_{k-1}, X; \gamma^{(c)})$ for any k, thus alleviating the need to further specify the function $c(k, M_k^c, C_k^{\text{obs}}, O_{k-1}, X; \gamma^{(c)})$. In the remaining models, we "borrowed strength" across treatment groups. Specifically, we assumed

$$\begin{aligned} a_{z}(k,\overline{O}_{k-1},X;\gamma^{(a)}) \\ &= \gamma_{0,0,k}^{(a)} + \gamma_{0,1,k}^{(a)}X + \gamma_{1}^{(a)}I(k>1)M_{k-1}^{c} + \gamma_{2}^{(a)}I(k>1)(1-M_{k-1}^{c})C_{k-1}^{obs} \\ &+ \gamma_{3}^{(a)}I(k>1)M_{k-1}^{s} + \gamma_{4}^{(a)}I(k>1)(1-M_{k-1}^{s})S_{k-1}^{obs} + \gamma_{5}^{(a)}z, \\ b_{z}(k,\overline{O}_{k-1},X;\gamma^{(b)}) \\ &= \gamma_{0,k}^{(b)} + \gamma_{1}^{(b)}I(k>1)M_{k-1}^{c} + \gamma_{2}^{(b)}I(k>1)(1-M_{k-1}^{c})C_{k-1}^{obs} \\ &+ \gamma_{3}^{(b)}I(k>1)M_{k-1}^{s} + \gamma_{4}^{(b)}I(k>1)(1-M_{k-1}^{s})S_{k-1}^{obs} + \gamma_{5}^{(b)}z + \gamma_{6}^{(b)}X, \\ d_{z}(k,M_{k}^{c},C_{k}^{obs},\overline{O}_{k-1},X;\gamma^{(d)}) \end{aligned}$$

$$\begin{split} &= \gamma_{0,k}^{(d)} + \gamma_1^{(d)} M_k^c + \gamma_2^{(d)} (1 - M_k^c) C_k^{\text{obs}} + \gamma_3^{(d)} (1 - M_k^c) C_k^{\text{obs}} X \\ &+ \gamma_4^{(d)} I(k > 1) M_{k-1}^c + \gamma_5^{(d)} I(k > 1) (1 - M_{k-1}^c) C_{k-1}^{\text{obs}} \\ &+ \gamma_6^{(d)} I(k > 1) M_{k-1}^s + \gamma_7^{(d)} I(k > 1) (1 - M_{k-1}^s) S_{k-1}^{\text{obs}} + \gamma_8^{(d)} z + \gamma_9^{(d)} X, \end{split}$$

where the functions are subscripted by treatment z (z = 0 denotes ethambutol, z = 1 denotes moxifloxacin).

Tables 2, 3 and 4 present estimates of the exponentiated parameters from these models, along with 95% nonparametric bootstrap percentile confidence intervals (based on 1000 resamples within treatment groups). In Table 2, missingness of sputum culture (aOR = 4.45; 95% CI: 2.03–9.70) and missingness of smear (aOR = 3.51; 95% CI: 1.52–9.66) at a previous visit are significant predictors of missingness of sputum culture at the next visit. In Table 3, among patients with an observed sputum culture at visit k, missingness of sputum culture (aOR = 4.00; 95% CI: 2.00–9.45), missingness of a smear (aOR = 5.16; 95% CI: 1.67–22.47), a negative observed culture (aOR = 6.37; 95% CI: 4.08–10.39) and a negative observed smear (aOR = 3.93; 95% CI: 2.51-6.18) at visit k-1, as well as assignment to the moxifloxacin arm (aOR = 2.06; 95% CI: 1.46–3.19), are significant predictors of a negative sputum culture at visit k. In Table 4, among patients with an observed smear at visit k, missingness of smear (aOR = 3.66; 95% CI: 1.45– 14.53) and an observed negative smear (aOR = 6.99; 95% CI: 4.50–11.81) at visit k-1, as well as an observed negative sputum culture at visit k (aOR = 10.73; 95% CI: 5.58-31.18), are significant predictors of a negativesmear at visit k.

Under our benchmark assumption, the estimated hazard ratio is 3.41 (95% CI: [1.33, 13.06]), indicating that patients treated with moxifloxacin have a statistically significant shorter time of culture conversion than those treated with ethambutol. Figure 3 displays a contour plot of the estimated odds ratio as a function of α_0 and α_1 . The region in white indicates combinations of α_0 and α_1 where the lower bound of the 95% confidence interval is less than 1. The gray region indicates combinations of α_0 and α_1 where the null of no treatment difference is rejected in favor of moxifloxacin.

Inference would change relative to the benchmark assumption (circle in Figure 3) if, say, $\alpha_0 = 5.0, \alpha_1 = -3.0$ (triangle in Figure 3) or $\alpha_0 =$ $-4.0, \alpha_1 = -10.0$ (square in Figure 3). At these combination of treatmentspecific sensitivity-analysis parameters, the estimated treatment effects are 2.19 (95% CI: 1.00–14.51) and 2.07 (95% CI: 0.97–5.38). To understand whether these combinations are "far" from the benchmark assumption, consider Figure 4. In the first row, we plot for each treatment group the estimated distribution of time of culture conversion for these sensitivity-analysis parameters (dashed and dotted lines) and the estimated distributions under

TABLE 2

(Exponentiated) parameter estimates and 95% confidence intervals from the model for missingness of culture results. See $a_z(k, \overline{O}_{k-1}, X; \gamma^{(a)})$ for form of the model

Intercept	Odds	95% CI
Wk 1 $(\exp(\gamma_{0,0,1}^{(a)}))$	0.14	[0.04, 0.30]
Wk 2 $(\exp(\gamma_{0,0,2}^{(a)}))$	0.11	[0.03, 0.24]
Wk 3 $(\exp(\gamma_{0,0,3}^{(a)}))$	0.03	[0.00, 0.09]
Wk 4 $(\exp(\gamma_{0,0,4}^{(a)}))$	0.11	[0.03, 0.25]
Wk 5 $(\exp(\gamma_{0,0,5}^{(a)}))$	0.07	[0.01, 0.19]
Wk 6 $(\exp(\gamma_{0,0,6}^{(a)}))$	0.04	[0.00, 0.12]
Wk 7 $(\exp(\gamma_{0,0,7}^{(a)}))$	0.05	[0.00, 0.14]
Wk 8 $(\exp(\gamma_{0,0,8}^{(a)}))$	0.07	[0.01, 0.18]
Predictor	Odds rati	io 95% CI
Wk 1*Cav $(\exp(\gamma_{0,1,1}^{(a)}))$	0.19	[0.00, 0.90]
Wk 2*Cav $(\exp(\gamma_{0,1,2}^{(a)}))$	0.21	[0.00, 0.87]
Wk 3*Cav $(\exp(\gamma_{0,1,3}^{(a)}))$	2.93	$[0.81,\infty]^{\dagger}$
Wk 4*Cav $(\exp(\gamma_{0,1,4}^{(a)}))$	0.38	[0.09, 1.50]
Wk 5*Cav $(\exp(\gamma_{0,1,5}^{(a)}))$	1.63	[0.55, 11.28]
Wk 6*Cav $(\exp(\gamma_{0,1,6}^{(a)}))$	1.39	$[0.36,\infty]^{\dagger}$
Wk 7*Cav $(\exp(\gamma_{0,1,7}^{(a)}))$	1.60	$[0.47,\infty]^{\dagger}$
Wk 8*Cav $(\exp(\gamma_{0,1,8}^{(a)}))$	1.63	[0.51, 8.32]
$I(k > 1)M_{k-1}^c (\exp(\gamma_1^{(a)}))$	4.45	[2.03, 9.70]
$I(k>1)(1-M_{k-1}^c)C_{k-1}^{obs}(\exp(\gamma_2^{(a)}))$) 0.89	[0.50, 1.68]
$I(k > 1)M_{k-1}^{s} (\exp(\gamma_{3}^{(a)}))$	3.51	[1.52, 9.66]
$I(k > 1)(1 - M_{k-1}^s)S_{k-1}^{obs}(\exp(\gamma_4^{(a)}))$	1.28	[0.72, 2.28]
Moxifloxacin $(\exp(\gamma_5^{(a)}))$	1.07	[0.67, 1.76]

 $^{\dagger}\infty$ here means a big number.

the benchmark assumption (solid lines). In the second row, we plot for each treatment group the signed Kolmogorov distance between the estimated distribution of time of culture conversion for given α and the estimated distribution function of time of culture conversion under the benchmark assumption. The signed Kolmogorov distance for treatment group z with sensitivity analysis parameter α_z equals $\hat{F}_z(k_z^*; \alpha_z) - \hat{F}_z(k_z^*; 0)$, where

$$k_z^* = \underset{k}{\operatorname{argmax}} |\widehat{F}_z(k;\alpha_z) - \widehat{F}_z(k;0)|$$

TABLE 3

(Exponentiated) parameter estimates and 95% confidence intervals from the model for negative culture results. See $b_z(k, \overline{O}_{k-1}, X; \gamma^{(b)})$ for form of the model

Intercept	Odds	95% CI
Wk 1 $(\exp(\gamma_{0,1}^{(b)}))$	0.04	[0.02, 0.08]
Wk 2 $(\exp(\gamma_{0,2}^{(b)}))$	0.03	[0.02, 0.06]
Wk 3 $(\exp(\gamma_{0,3}^{(b)}))$	0.08	[0.04, 0.14]
Wk 4 $(\exp(\gamma_{0,4}^{(b)}))$	0.10	[0.05, 0.18]
Wk 5 $(\exp(\gamma_{0,5}^{(b)}))$	0.10	[0.05, 0.17]
Wk 6 $(\exp(\gamma_{0,6}^{(b)}))$	0.24	[0.13, 0.41]
Wk 7 $(\exp(\gamma_{0,7}^{(b)}))$	0.22	[0.12, 0.40]
Wk 8 $(\exp(\gamma_{0,8}^{(b)}))$	0.49	[0.26, 0.95]
Predictor	Odds rati	io 95% CI
$I(k>1)M_{k-1}^c (\exp(\gamma_1^{(b)}))$	4.00	[2.00, 9.45]
$I(k>1)(1-M_{k-1}^c)C_{k-1}^{\rm obs}\ (\exp(\gamma_2^{(b)}))$	6.37	[4.08, 10.39]
$I(k > 1)M_{k-1}^s (\exp(\gamma_3^{(b)}))$	5.16	[1.67, 22.47]
$I(k>1)(1-M_{k-1}^s)S_{k-1}^{\rm obs}\ (\exp(\gamma_4^{(b)}))$	3.93	[2.51, 6.18]
Moxifloxacin $(\exp(\gamma_5^{(b)}))$	2.06	[1.46, 3.19]
Cavitation $(\exp(\gamma_6^{(b)}))$	1.16	[0.81, 1.75]

and $\hat{F}_z(k;\alpha_z)$ is the estimated cumulative distribution function. When $\alpha_0 =$ 5.0 and $\alpha_1 = -3.0$, the signed distances for the ethambutol and moxifloxacin arms are 0.047 and -0.11, the latter being a fairly sizable difference (for the moxifloxacin arm, the estimated probability of culture conversion by visit 5 is 49.6% under the benchmark assumption and 38.2% when $\alpha_1 = -3.0$). Further, the distances are of opposite signs (i.e., the bias differs between arms). When we look at other combinations of sensitivity-analysis parameters where the null hypothesis is not rejected, the sensitivity-analysis parameter for the moxifloxacin arm is less than or equal to -3.0 and the associated signed distances are at least as extreme as -0.11. When $\alpha_0 = -4.0$ and $\alpha_1 = -10.0$, the signed distances are -0.11 and -0.16 for the ethambutol and moxifloxacin arms, respectively. Here the signs are in the same direction, but the choice of sensitivity-analysis parameters yields results that are very close to the worst-case bounds that assume that all missing cultures are positive. From a clinical perspective, inferences relative to the benchmark assumption are fairly robust.

TABLE 4
(Exponentiated) parameter estimates and 95% confidence
intervals from the model for smear results. See
$d_z(k, M_k^c, C_k^{obs}, \overline{O}_{k-1}, X; \gamma^{(d)})$ for form of the model

Intercept	Odds	95% CI
Wk 1 $(\exp(\gamma_{0,1}^{(d)}))$	0.25	[0.13, 0.42]
Wk 2 $(\exp(\gamma_{0,2}^{(d)}))$	0.34	[0.20, 0.56]
Wk 3 $(\exp(\gamma_{0,3}^{(d)}))$	0.35	[0.21, 0.58]
Wk 4 $(\exp(\gamma_{0,4}^{(d)}))$	0.21	[0.11, 0.37]
Wk 5 $(\exp(\gamma_{0,5}^{(d)}))$	0.35	[0.19, 0.65]
Wk 6 $(\exp(\gamma_{0,6}^{(d)}))$	0.20	[0.10, 0.39]
Wk 7 $(\exp(\gamma_{0,7}^{(d)}))$	0.23	[0.12, 0.43]
Wk 8 $(\exp(\gamma_{0,8}^{(d)}))$	0.24	[0.11, 0.53]
Predictor	Odds rati	o 95% CI
$\overline{M_k^c}\left(\exp(\gamma_1^{(d)})\right)$	1.24	[0.61, 2.61]
$(1 - M_k^c)C_k^{\rm obs} \left(\exp(\gamma_2^{(d)})\right)$	10.73	[5.58, 31.18]
$(1 - M_k^c)C_k^{\text{obs}} \cdot \text{Cav} (\exp(\gamma_3^{(d)}))$	0.46	[0.16, 1.04]
$I(l > 1) MC \qquad (a = (a (d)))$	1.52	[0.66, 3.46]
$I(k > 1)M_{k-1}^c (\exp(\gamma_4^{(d)}))$	1.04	[0.00, 5.40]
$I(k > 1)M_{k-1} (\exp(\gamma_4^{(d)}))$ $I(k > 1)(1 - M_{k-1}^c)C_{k-1}^{obs} (\exp(\gamma_5^{(d)}))$		[0.92, 2.38]
() 10 1 (1 () 4))		. / .
$I(k>1)(1-M_{k-1}^c)C_{k-1}^{obs}(\exp(\gamma_5^{(d)}))$	1.44	[0.92, 2.38]
$I(k>1)(1 - M_{k-1}^c)C_{k-1}^{obs}(\exp(\gamma_5^{(d)}))$ $I(k>1)M_{k-1}^s(\exp(\gamma_6^{(d)}))$	$1.44 \\ 3.66$	[0.92, 2.38] [1.45, 14.53]

5. Discussion. Conde et al. (2009) did not compare the treatments with respect to time of culture conversion. Rather, they compared the treatment-specific probabilities of being a culture converter at or prior to week 8, which is equivalent to having a negative culture at week 8. They used two methods. The primary method assumed that all missing cultures at week 8 were positive (moxifloxacin: 77.0%; ethambutol: 62.5%; difference: 14.5 percentage points, 95% CI [-0.0 percentage points, 29.0 percentage points]); the secondary method excluded patients who were missing their week 8 culture, assuming that the missing cultures were missing completely at random (moxifloxacin: 90.5%; ethambutol: 73.8%; difference: 16.7 percentage points, 95% CI [3.4 percentage points, 30.4 percentage points]). The former analysis was not statistically significant, whereas the latter analysis did suggest a statistically significant treatment effect in favor of moxifloxacin. Their anal-




FIG. 3. Contour plot of the estimated ratio of the odds of first becoming a culture converter at visit k given culture conversion at or after visit k, comparing moxifloxacin vs. ethambutol as a function of the sensitivity-analysis parameters α_0 and α_1 . The region in white indicates combinations of α_0 and α_1 where the lower bound of the 95% confidence interval is less than 1. The gray region indicates combinations of α_0 and α_1 where the null of no treatment difference is rejected in favor of moxifloxacin. The circle denotes the benchmark assumption ($\alpha_0 = 0.0, \alpha_1 = 0.0$). The triangle ($\alpha_0 = 5, \alpha_1 = -3$) and square ($\alpha_0 = -4, \alpha_1 = -10$) denote two combinations discussed in the text.

ysis made no attempt to account for imbalance in baseline cavitation status between treatment groups.

It is tempting to think that this problem can be addressed by simply analyzing the culture results using standard statistical methods for longitudinal binary data (e.g., marginal models and generalized linear mixed models). A marginal model, fit using generalized estimating equations, identifies, under the assumption that the culture results are missing completely at random, the probability of a negative culture at each visit k; it does not admit identification of the distribution of time of culture conversion. In contrast, a generalized linear mixed model is a fully parametric model for the joint distribution of the culture results and, under the missing at random assumption, admits identification of the distribution of time of culture conversion. However, the modeling assumptions are too strong, as they essentially allow the "imputation" of missing culture results that are not needed to identify the distribution of interest (e.g., the imputation of missing cultures that are followed by positive cultures). Further, the model induces testable restrictions, and, as discussed by Robins and Gill (1997), the missing-at-random assumption is often unrealistic in follow-up studies with intermittent missing data. Nonetheless, we fit a logistic-normal generalized linear mixed model to the culture data with fixed effects for time, treatment and cavitation and a random intercept. Using the model, we estimated, within levels of time, treatment and cavitation, the induced probability of a negative culture among those with missing cultures. Many of the estimated probabilities were either greater than 1 or less than 0, suggesting inadequate model fit.




FIG. 4. First row: Treatment-specific estimated distribution of time of culture conversion for the benchmark and alternative sensitivity-analysis parameters considered in the text. Second row: For each treatment group, the signed Kolmogorov distance between the estimated distribution of time of culture conversion for given α and the estimated distribution function of time of culture conversion under the benchmark assumption.

An alternative way of analyzing the culture data would treat the data for each patient as the set of times of culture conversion that are consistent with their observed culture data (i.e., the coarsening set) and estimate the distribution of time to culture conversion under the coarsening-at-random (CAR) assumption [Gill, Van der Laan and Robins (1997), Heitjan (1993, 1994), Heitjan and Rubin (1991)]. This assumption states that the coarsening process provides no information about the time of culture conversion beyond conveying that the true event time is in the observed coarsening set. Under CAR, the coarsening process is "ignorable" (i.e., it factors out of

the likelihood for the observed data). Under this assumption, the estimated value of β is 2.92 (95% CI: 1.09–11.95). The result is statistically significant and favors moxifloxacin.

We have assumed, as in most analyses of culture conversion data, that the test results are measured without error. We know that this is not correct. It would be interesting to use known information about the sensitivity and specificity of the culture and smear procedures to learn about the "true" distribution of time of culture conversion. This will be the subject of future research.

In our analysis, we did not have access to the reasons for missingness. We know them to be a combination of three main sources: culture contamination, inability to produce sputum and skipped clinic visits. For the former two reasons, the culture results are more likely to be negative. Contamination of sputum cultures with bacteria from the mouth and airways occurs in 2–10% of specimens and varies by laboratory. Patients producing smaller amounts of sputum that is mixed with saliva are more likely to have contamination; therefore, patients who have responded to therapy (i.e., have negative cultures) and no longer are producing large volumes of sputum may be more likely to have a contaminated specimen. Patients with treated tuberculosis who can no longer produce sputum are also likely to have responded to therapy and have negative cultures. If most of the missing data are due to these two causes, it is not so surprising that the results of the benchmark analysis are so close to the "best-case" bounds.

In summary, we introduced a novel benchmark assumption that allows us to "learn" about the distribution of just those unknown culture results that are absolutely necessary to identify the distribution of time of culture conversion by "borrowing strength" from patients who are as similar as possible (with respect to baseline cavitation status, treatment assignment, and observed culture and sputum results) and on whom the distribution of these culture results is identified. We evaluated the sensitivity of inferences to our benchmark assumption by embedding it in a class of model assumptions indexed by sensitivity-analysis parameters. Although the sensitivity-analysis parameters themselves are not scientifically interpretable, the induced distribution of time of culture conversion (and functionals thereof) can be estimated and compared with that under the benchmark assumption. If the differences are judged "large" by scientific experts, we hope that they will comment on the fragility or robustness of the benchmark inference. Except in rare settings where the treatment effects are so dramatic or missing data are so minor, we see no alternatives to sensitivity analysis aided by scientific judgement.

The ideas described in this article can be applied to any study design in which an enrolled subject is expected to undergo a fixed sequence of "pass/fail" tests, one or more test results may be missing, and interest focuses on estimating the distribution of the earliest test at which a subject "passes" ("fails") that and all subsequent tests. For example, the methods described here would be highly relevant for analyzing studies of treatment of hepatitis C virus (HCV) infection with antiviral therapy, particularly in light of new and highly active direct-acting agents. In these studies, patients are typically treated for 24 or 48 weeks, with HCV viral load measured repeatedly during and after treatment [see, e.g., Nelson et al. (2012)]. Here a "pass" denotes HCV viral load below the limit of detection. Additionally, the methods can be easily adapted to address the classic discrete-time interval-censoring problem where each coarsening set consists of either one time point or a collection of contiguous time points.

APPENDIX

A straightforward application of the law of total probability entails that under models (3.6)-(3.9),

$$P[T = k | \mathbf{O} = \mathbf{o}^{(k-1)}; \gamma] = \frac{g_{k-1}(0, O_k, X; \gamma)}{\sum_{y=0}^{1} g_{k-1}(y, \overline{O}_k, X; \gamma)},$$

where

$$g_{k}(y,\overline{O}_{k+1},X;\gamma) = (1 - \exp it\{a(k+1,O_{k}(0,y),X;\gamma^{(a)})\}) \\ \times \exp it\{b(k,O_{k-1},X;\gamma^{(b)})\}^{y} \\ \times (1 - \exp it\{b(k,O_{k-1},X;\gamma^{(b)})\})^{(1-y)} \\ \times \exp it\{b(k+1,O_{k}(0,y),X;\gamma^{(b)})\} \\ \times (1 - \exp it\{c(k,0,y,O_{k-1},X;\gamma^{(c)})\})^{(1-M_{k}^{s})} \\ \times \exp it\{c(k,0,y,O_{k-1},X;\gamma^{(c)})\}^{M_{k}^{s}} \\ \times (1 - \exp it\{c(k+1,0,1,O_{k}(0,y),X;\gamma^{(c)})\})^{(1-M_{k+1}^{s})} \\ \times \exp it\{c(k+1,0,1,O_{k}(0,y),X;\gamma^{(c)})\}^{M_{k+1}^{s}} \\ \times (1 - \exp it\{d(k,0,y,O_{k-1},X;\gamma^{(d)})\})^{(1-S_{k})} \\ \times \exp it\{d(k,0,y,O_{k-1},X;\gamma^{(d)})\})^{(1-S_{k+1})} \\ \times \exp it\{d(k+1,0,1,O_{k}(0,y),X;\gamma^{(d)})\})^{(1-S_{k+1})} \\ \times \exp it\{d(k+1,0,1,O_{k}(0,y),X;\gamma^{(d)})\}^{S_{k+1}}$$

and $O_k(0, y)$ represents observed data at visit k with M_k^c set to 0 and C_k set to y.

If $c(j, M_j^c, C_j^{\text{obs}}, O_{j-1}, X; \gamma^{(c)})$ does not depend on C_j^{obs} and C_{j-1}^{obs} for all j, then $P[T = k | O = o^{(k-1)}; \gamma]$ does not depend on $\gamma^{(c)}$.

Acknowledgments. The authors would like to thank Jonghyeon Kim, Chad Heilig, Malathi Ram, Pei-Jean Feng and Swarnadip Ghosh for assistance during the conduct of this research. The authors would also like to thank the Associate Editor and two anonymous referees who, through their detailed and critical reviews, greatly improved the quality of the manuscript.

REFERENCES

- AMERICAN THORACIC SOCIETY (2000). Diagnostic standards and classification of tuberculosis in adults and children. Am. J. Respir. Crit. Care Med. 161 1376–1395.
- BARNDORFF-NIELSEN, O. E. and COX, D. R. (1994). Inference and Asymptotics. Chapman & Hall, London. MR1317097
- CONDE, M. B., EFRON, A., LOREDO, C., SOUZA, G. R. M. D., GRAÇA, N. P., CEZAR, M. C., RAM, M., CHAUDHARY, M. A., BISHAI, W. R., KRITSKI, A. L. and CHAISSON, R. E. (2009). Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: A double-blind, randomised, controlled phase II trial. *Lancet* 373 1183– 1189.
- Cox, D. R. (1972). Regression models and life-tables. J. Roy. Statist. Soc. Ser. B 34 187–220. MR0341758
- EUROPEAN MEDICINES AGENCY, COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (2010). Addendum to the Note for Guidance on Evaluation of Medicinal Products Indicated for Treatment of Bacterial Infections to Specifically Address the Clinical Development of New Agents to Treat Disease Due to Mycobacterium Tuberculosis. European Medicines Agency, London.
- GILL, R. D., VAN DER LAAN, M. J. and ROBINS, J. M. (1997). Coarsening at random: Characterizations, conjectures and counter-examples. In *Proceedings of the First Seattle Symposium in Biostatistics: Survival Analysis* (D. Y. LIN and T. R. FLEMING, eds.) 255–294. Springer, Berlin.
- HEITJAN, D. F. (1993). Ignorability and coarse data: Some biomedical examples. *Biomet*rics 49 1099–1109.
- HEITJAN, D. F. (1994). Ignorability in general incomplete-data models. Biometrika 81 701–708. MR1326420
- HEITJAN, D. F. and RUBIN, D. B. (1991). Ignorability and coarse data. Ann. Statist. 19 2244–2253. MR1135174
- NELSON, D. R., ZEUZEM, S., ANDREONE, P., FERENCI, P., HERRING, R., JENSEN, D. M., MARCELLIN, P., POCKROS, P. J., RODRÍGUEZ-TORRES, M., ROSSARO, L. et al. (2012). Balapiravir plus peginterferon alfa-2a (40KD)/ribavirin in a randomized trial of hepatitis C genotype 1 patients. Annals of Hepatology 11 15.
- NEWEY, W. K. and MCFADDEN, D. (1994). Large sample estimation and hypothesis testing. In *Handbook of Econometrics, Vol. IV* (R. F. ENGLE and D. L. MCFADDEN, eds.) 2111–2245. North-Holland, Amsterdam. MR1315971
- ROBINS, J. M. and GILL, R. D. (1997). Non-response models for the analysis of nonmonotone ignorable missing data. *Stat. Med.* **16** 39–56.

TUBERCULOSIS STUDIES WITH MISSING SPUTUM DATA

D. Scharfstein A. McDermott Department of Biostatistics Johns Hopkins Bloomberg School of Public Health 615 North Wolfe Street Baltimore, Maryland 21205 USA E-Mail: dscharf@jhu.edu amcderm1@jhu.edu

M. ABRAHAM STATISTICS COLLABORATIVE 1625 MASSACHUSETTS AVE NW SUITE 600 WASHINGTON, DC 20036 USA E-MAIL: maria.abraham4@gmail.com A. ROTNITZKY CONICET Department of Economics Universidad Torcuato Di Tella Saenz Valiente 1010 1428 Buenos Aires Argentina E-mail: arotnitzky@utdt.edu

R. Chaisson Johns Hopkins Center for Tuberculosis Research 1550 Orleans St., 1M.08 Baltimore, Maryland 21231 USA E-mail: rchaiss@jhmi.edu

L. GEITER OTSUKA NOVEL PRODUCTS-TB OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION, INC. 2440 RESEARCH BOULEVARD ROCKVILLE, MARYLAND 20850 USA E-MAIL: Lawrence.Geiter@otsuka-us.com